View ValuationChoA Pharmaceutical 将来の成長Future 基準チェック /06現在、 ChoA Pharmaceuticalの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長22.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.6b free cash flow). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩26.5b market cap, or US$17.2m).Reported Earnings • Mar 18Full year 2025 earnings released: ₩220 loss per share (vs ₩310 loss in FY 2024)Full year 2025 results: ₩220 loss per share (improved from ₩310 loss in FY 2024). Revenue: ₩59.3b (down 5.4% from FY 2024). Net loss: ₩6.81b (loss narrowed 29% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.お知らせ • Feb 20ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 23, 2026ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 23, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 12, dangsan-ro 2-gil, yeongdeungpo-gu, seoul South Korea分析記事 • Feb 06Unpleasant Surprises Could Be In Store For ChoA Pharmaceutical Co., LTD.'s (KOSDAQ:034940) SharesThere wouldn't be many who think ChoA Pharmaceutical Co., LTD.'s ( KOSDAQ:034940 ) price-to-sales (or "P/S") ratio of...New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩8.6b free cash flow). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (₩34.9b market cap, or US$25.0m).分析記事 • Sep 05ChoA Pharmaceutical (KOSDAQ:034940) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Reported Earnings • Mar 19Full year 2024 earnings released: ₩310 loss per share (vs ₩339 loss in FY 2023)Full year 2024 results: ₩310 loss per share (improved from ₩339 loss in FY 2023). Revenue: ₩62.7b (flat on FY 2023). Net loss: ₩9.60b (loss narrowed 8.7% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 33% per year and the company’s share price has also fallen by 33% per year.お知らせ • Feb 22ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 24, 2025ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 12, dangsan-ro 2-gil, yeongdeungpo-gu, seoul South Korea分析記事 • Dec 09Some ChoA Pharmaceutical Co., LTD. (KOSDAQ:034940) Shareholders Look For Exit As Shares Take 31% PoundingTo the annoyance of some shareholders, ChoA Pharmaceutical Co., LTD. ( KOSDAQ:034940 ) shares are down a considerable...New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$19.9m).New Risk • Nov 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩5.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.6b free cash flow). Earnings have declined by 33% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩29.2b market cap, or US$20.9m).分析記事 • Nov 12ChoA Pharmaceutical (KOSDAQ:034940) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Aug 12Would ChoA Pharmaceutical (KOSDAQ:034940) Be Better Off With Less Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 20Full year 2023 earnings released: ₩339 loss per share (vs ₩18.00 profit in FY 2022)Full year 2023 results: ₩339 loss per share (down from ₩18.00 profit in FY 2022). Revenue: ₩63.0b (down 8.6% from FY 2022). Net loss: ₩10.5b (down ₩11.1b from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.New Risk • Nov 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.0b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.0b free cash flow). Earnings have declined by 21% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.4b market cap, or US$50.6m).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Is New 90 Day High Low • Feb 24New 90-day low: ₩4,510The company is down 10.0% from its price of ₩5,010 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.分析記事 • Jan 31ChoA PharmaceuticalLtd (KOSDAQ:034940) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Jan 28New 90-day low: ₩4,710The company is down 1.0% from its price of ₩4,760 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.Is New 90 Day High Low • Dec 21New 90-day high: ₩5,290The company is up 9.0% from its price of ₩4,850 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.分析記事 • Dec 09Did You Miss ChoA PharmaceuticalLtd's (KOSDAQ:034940) 36% Share Price Gain?It's always best to build a diverse portfolio of shares, since any stock business could lag the broader market. But the...Is New 90 Day High Low • Oct 26New 90-day low: ₩4,600The company is down 7.0% from its price of ₩4,955 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ChoA Pharmaceutical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A034940 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202659,620-4,727-5,555-3,518N/A12/31/202559,311-6,806-6,202-4,180N/A9/30/202560,500-7,659-5,796-4,051N/A6/30/202560,258-10,100-8,593-6,943N/A3/31/202561,931-10,129-6,089-5,199N/A12/31/202462,694-9,605-5,249-4,468N/A9/30/202461,461-13,072-5,625-4,784N/A6/30/202461,032-12,889-4,328-3,603N/A3/31/202462,264-12,212-2,678-2,226N/A12/31/202362,974-10,514-2,418-1,475N/A9/30/202366,586-690-3,988-2,042N/A6/30/202368,2131,960-2,752-535N/A3/31/202369,1031,900-3,618-754N/A12/31/202268,880561-4,365-1,443N/A9/30/202264,523-5,203-5,388-2,712N/A6/30/202262,833-7,061-6,680-2,869N/A3/31/202259,475-8,042-6,782-2,621N/A12/31/202157,561-8,044-5,344-1,480N/A9/30/202157,331-6,084-3,976-16N/A6/30/202158,238-4,142-2,569228N/A3/31/202161,611-1,649-2,231417N/A12/31/202065,360-1,319-1,7191,922N/A9/30/202068,683-6691,3944,184N/A6/30/202069,689-1,5561533,250N/A3/31/202069,193-2,0901,4634,063N/A12/31/201967,537-905N/A4,157N/A9/30/201965,967-2,063N/A2,520N/A6/30/201964,459-685N/A1,805N/A3/31/201963,804608N/A2,512N/A12/31/201863,090641N/A2,044N/A9/30/201862,0103,412N/A2,107N/A6/30/201862,2643,131N/A2,948N/A3/31/201860,7812,365N/A427N/A12/31/201758,8651,624N/A-676N/A9/30/201758,394590N/A-1,150N/A6/30/201756,679323N/A267N/A3/31/201755,867-342N/A1,026N/A12/31/201655,551163N/A930N/A9/30/201653,940730N/A558N/A6/30/201653,093936N/A641N/A3/31/201651,7811,030N/A-463N/A12/31/201550,1201,012N/A1,187N/A9/30/201548,007-1,448N/A2,187N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A034940の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A034940の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A034940の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A034940の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A034940の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A034940の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 21:22終値2026/07/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ChoA Pharmaceutical Co., LTD. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.6b free cash flow). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩26.5b market cap, or US$17.2m).
Reported Earnings • Mar 18Full year 2025 earnings released: ₩220 loss per share (vs ₩310 loss in FY 2024)Full year 2025 results: ₩220 loss per share (improved from ₩310 loss in FY 2024). Revenue: ₩59.3b (down 5.4% from FY 2024). Net loss: ₩6.81b (loss narrowed 29% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 20ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 23, 2026ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 23, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 12, dangsan-ro 2-gil, yeongdeungpo-gu, seoul South Korea
分析記事 • Feb 06Unpleasant Surprises Could Be In Store For ChoA Pharmaceutical Co., LTD.'s (KOSDAQ:034940) SharesThere wouldn't be many who think ChoA Pharmaceutical Co., LTD.'s ( KOSDAQ:034940 ) price-to-sales (or "P/S") ratio of...
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩8.6b free cash flow). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (₩34.9b market cap, or US$25.0m).
分析記事 • Sep 05ChoA Pharmaceutical (KOSDAQ:034940) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Reported Earnings • Mar 19Full year 2024 earnings released: ₩310 loss per share (vs ₩339 loss in FY 2023)Full year 2024 results: ₩310 loss per share (improved from ₩339 loss in FY 2023). Revenue: ₩62.7b (flat on FY 2023). Net loss: ₩9.60b (loss narrowed 8.7% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 33% per year and the company’s share price has also fallen by 33% per year.
お知らせ • Feb 22ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 24, 2025ChoA Pharmaceutical Co., LTD., Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 12, dangsan-ro 2-gil, yeongdeungpo-gu, seoul South Korea
分析記事 • Dec 09Some ChoA Pharmaceutical Co., LTD. (KOSDAQ:034940) Shareholders Look For Exit As Shares Take 31% PoundingTo the annoyance of some shareholders, ChoA Pharmaceutical Co., LTD. ( KOSDAQ:034940 ) shares are down a considerable...
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$19.9m).
New Risk • Nov 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩5.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.6b free cash flow). Earnings have declined by 33% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩29.2b market cap, or US$20.9m).
分析記事 • Nov 12ChoA Pharmaceutical (KOSDAQ:034940) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Aug 12Would ChoA Pharmaceutical (KOSDAQ:034940) Be Better Off With Less Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 20Full year 2023 earnings released: ₩339 loss per share (vs ₩18.00 profit in FY 2022)Full year 2023 results: ₩339 loss per share (down from ₩18.00 profit in FY 2022). Revenue: ₩63.0b (down 8.6% from FY 2022). Net loss: ₩10.5b (down ₩11.1b from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
New Risk • Nov 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.0b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.0b free cash flow). Earnings have declined by 21% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.4b market cap, or US$50.6m).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Is New 90 Day High Low • Feb 24New 90-day low: ₩4,510The company is down 10.0% from its price of ₩5,010 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
分析記事 • Jan 31ChoA PharmaceuticalLtd (KOSDAQ:034940) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Jan 28New 90-day low: ₩4,710The company is down 1.0% from its price of ₩4,760 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
Is New 90 Day High Low • Dec 21New 90-day high: ₩5,290The company is up 9.0% from its price of ₩4,850 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.
分析記事 • Dec 09Did You Miss ChoA PharmaceuticalLtd's (KOSDAQ:034940) 36% Share Price Gain?It's always best to build a diverse portfolio of shares, since any stock business could lag the broader market. But the...
Is New 90 Day High Low • Oct 26New 90-day low: ₩4,600The company is down 7.0% from its price of ₩4,955 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.